MétaCan
Menu
← Back to cohort

S2426 Development of De Novo Ulcerative Colitis While on Etanercept for Rheumatoid Arthritis

2021· article· en· W3210900866 on OpenAlexaff
Rachael Chan, Sowmya Sharma, Ian Epstein

Bibliographic record

VenueThe American Journal of Gastroenterology · 2021
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsSaint John Regional HospitalDalhousie University
Fundersnot available
KeywordsMedicineEtanerceptUlcerative colitisGastroenterologyRheumatoid arthritisInternal medicineInfliximabRectumLeflunomidePerforationSurgeryTumor necrosis factor alpha

Abstract

fetched live from OpenAlex

Introduction: Treatment of chronic inflammatory diseases, including inflammatory bowel diseases (IBD), has been revolutionized by anti-tumor necrosis factor-alpha (anti-TNFα) agents. Paradoxically, treatment with anti-TNFα agents may provoke development of de novo IBD. The nature of this association is uncertain, but has been described while on treatment with etanercept, an anti-TNFα agent. We describe a case of de novo ulcerative colitis (UC) in a patient being treated with etanercept for rheumatoid arthritis (RA). Case description/methods: A 55-year-old female with RA treated with etanercept and leflunomide presented to the emergency department with a 5-week history of hematochezia occurring 5-6 times per day, abdominal pain, increasing fatigue, and weight loss of 20 lbs. Investigations revealed a C-reactive protein of 249 mg/L, hemoglobin of 116 g/L, platelet count of 523 x 109/L, and white blood cell count of 11.7 x 109/L. Stool culture, including C.difficile antigen, and ova and parasite exam were negative. Abdominal radiograph did not show toxic megacolon. Flexible sigmoidoscopy showed mild to moderate erythema from the rectum to 25cm and severe inflammation with deep ulceration from 25-40cm. Computerized tomography of the abdomen and pelvis did not show evidence of perforation, but there was circumferential mural thickening involving the entire colon and lack of small bowel thickening or dilation. Given this, the patient was started on IV methylprednisolone for in-hospital induction. Discussion: Biopsies of the sigmoid colon and rectum showed moderately active chronic colitis, crypt architectural distortion, crypt abscesses, and basal lymphoplasmacytic inflammation, lacking granulomas. Discussion between treating gastroenterologist and rheumatologist led to discontinuation of leflunomide and etanercept and starting vedolizumab while completing an oral steroid taper. Although the patient’s RA was controlled on etanercept, it was stopped due to concerns of exacerbating the de novo UC. This rationale led to selection of vedolizumab, rather than infliximab or adalimumab, as it has an alternative biologic mechanism. After discontinuation of oral steroids, the patient’s RA flared and methotrexate combination therapy was initiated. Since starting vedolizumab, her UC symptoms have remained in remission. This case illustrates the potential development of de novo UC while being treated with an anti-TNFα agent. Its recognition is imperative to a timely diagnosis and initiation of appropriate therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Case report · Consensus signal: Case report
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.023

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0070.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.240
Teacher spread0.232 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designCase report
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicInflammatory Bowel Disease→French-language works237,207→